NCT06845202 - A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM | Biotech Hunter

Enrollment

144

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions

Obese or Overweight Healthy VolunteersType 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

ALN-4324

ALN-4324 will be administered subcutaneously (SC)

DRUG

Placebo

Placebo will be administered SC

Trial Locations (18)

20009

NOT_YET_RECRUITING

Clinical Trial Site, Washington D.C.

27612

NOT_YET_RECRUITING

Clinical Trial Site, Raleigh

28112

NOT_YET_RECRUITING

Clinical Trial Site, Monroe

33126

NOT_YET_RECRUITING

Clinical Trial Site, Miami

91763

NOT_YET_RECRUITING

Clinical Trial Site, Montclair

08009

NOT_YET_RECRUITING

Clinical Trial Site, Berlin

Unknown

NOT_YET_RECRUITING

Clinical Trial Site, Buenos Aires

NOT_YET_RECRUITING

Clinical Trial Site, Mar del Plata

NOT_YET_RECRUITING

Clinical Trial Site, San Miguel de Tucumán

NOT_YET_RECRUITING

Clinical Trial Site, Vancouver

NOT_YET_RECRUITING

Clinical Trial Site, Concord

RECRUITING

Clinical Trial Site, Mount Royal

NOT_YET_RECRUITING

Clinical Trial Site, Santiago

NOT_YET_RECRUITING

Clinical Trial Site, Essen

NOT_YET_RECRUITING

Clinical Trial Site, Gdansk

NOT_YET_RECRUITING

Clinical Trial Site, Lublin

NOT_YET_RECRUITING

Clinical Trial Site, Tarnów

NOT_YET_RECRUITING

Clinical Trial Site, Warsaw